long intergenic non-protein coding RNA 2356Genealiases: []
Q-omics provides the consensus-scored LINC02356 profile across patient tissues and cancer cell-line models. LINC02356 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, LINC02356 is differentially expressed in 10, with the highest sampling consensus in LUSC. Additionally, LINC02356 RNA expression shows 11,790 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, LUSC, and TGCT as cancer lineages where LINC02356 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02356 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02356 survival associations across molecular data types. LINC02356 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02356 RNA expression–survival associations across cancer types. High LINC02356 expression shows unfavorable associations in LIHC, THCA and KICH, but favorable associations in CESC, ESCA and BLCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify LIHC as the clearest survival context for LINC02356 RNA expression.
This table summarizes LINC02356 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02356. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02356 shows lower tumor expression in LUSC, LUAD, BRCA, HNSC and KICH and higher tumor expression in KIRC. The LUSC box plot shows higher LINC02356 RNA expression in normal versus tumor tissue (log2 FC = −1.207, t-test p < 0.001).
This table shows molecular features associated with LINC02356 in patient tissues and cancer cell lines. In patient samples, LINC02356 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
